-
AstraZeneca Sets Sights on $80 Billion Revenue Target and 20 New Molecular Entities by 2030
•
At its recent investor day, AstraZeneca plc (NASDAQ: AZN), a prominent UK pharmaceutical company, articulated its long-term objectives to shareholders. The company outlined an ambitious plan to achieve revenues of $80 billion by 2030, which is nearly double the $45.8 billion reported in 2023. This target will be pursued by…
-
AstraZeneca Commits $1.5 Billion to Build Singapore-Based ADC Manufacturing Facility
•
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield investment to establish a manufacturing presence in Singapore with the construction of a state-of-the-art antibody-drug conjugate (ADC) production site. This facility will be the company’s first end-to-end manufacturing hub, handling all stages of ADC production,…
-
AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation
•
AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure target discovered by BenevolentAI (AMS: BAI), a UK-based precision drug design company. This milestone achievement marks a significant step in their ongoing partnership, which was initially established in 2019 with a focus on idiopathic pulmonary…
-
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
•
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates.…
-
AstraZeneca Hong Kong Launches ‘HRDetect’ Program to Offer Free Genetic Testing for Cancer Patients
•
AstraZeneca (AZ, NASDAQ: AZN) Hong Kong has announced a partnership with Inocras Hong Kong Ltd and Cancerinformation.com.hk Charity Foundation (CICF) to launch the “HRDetect” program in Hong Kong and Macau. This initiative will provide eligible cancer patients in both regions with complimentary BRCA or HRD genetic testing. The genetic testing…
-
U.S. Judge Dismisses Johnson & Johnson and Bristol-Myers Squibb Lawsuits Against Drug-Pricing Provisions in Inflation Reduction Act
•
In a recent legal development, a U.S. federal court judge has rejected the legal challenges brought by pharmaceutical giants Johnson & Johnson (J&J; NYSE: JNJ) and Bristol-Myers Squibb (BMS; NYSE: BMY) against the drug-price negotiations outlined in President Joe Biden’s Inflation Reduction Act (IRA). The companies had filed separate lawsuits…
-
Daiichi Sankyo Reports 25.3% Revenue Growth in FY2023, Boosted by Enhertu and Lixiana Sales
•
Japanese pharmaceutical company Daiichi Sankyo has reported a remarkable fiscal year 2023, with revenues increasing by 25.3% to ¥1.602 trillion (USD 10.05 billion) for the 12-month period ended March 31, 2024. The growth was primarily driven by the success of its HER2-targeted antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and…
-
Kexing Pharmaceutical Secures Global Rights for Qingfeng’s Generic Olaparib
•
China’s Kexing Pharmaceutical (SHA: 688136) has secured a global commercialization licensing agreement with Qingfeng Pharmaceutical Group for the latter’s generic version of olaparib. Under this deal, Kexing will obtain commercial rights for the product across an initial batch of 10 international markets. Meanwhile, Qingfeng’s generic formulation is currently awaiting regulatory…
-
AstraZeneca Reports 19% YOY Revenue Growth in Q1 2024, Driven by Oncology and R&I
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released an impressive set of financial results for the first quarter of 2024, with overall revenues increasing by 19% year-on-year (YOY) in constant currency terms to USD 12.68 billion. Product sales soared 18% YOY, reaching USD 12.18 billion. The company’s business units…
-
Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as the new Greater China Chief Commercial Officer (CCO), succeeding Liang Yi, who is departing from his role as both CCO and President of Greater China. Liang’s departure will become official on April 30. Zhu Tong’s…
-
Amgen’s Tezspire Shows Promise in Phase IIa COPD Trial, Reduces Exacerbations
•
Amgen (NASDAQ: AMGN), a multinational biopharmaceutical company, has this week announced results from a Phase IIa proof-of-concept trial for its anti-thymic stromal lymphopoietin (TSLP) biologic, Tezspire (tezepelumab), in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD). The trial indicated that Tezspire reduced the annualized rate of moderate or severe exacerbations…
-
AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial
•
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year results from a Phase III clinical trial of its anti-PD-L1 therapy Imfinzi (durvalumab) in combination with chemotherapy for the treatment of advanced biliary tract cancer (BTC). The trial, after a median follow-up of 41.3 months,…
-
AstraZeneca’s Fasenra Gains FDA Approval for Pediatric Severe Asthma Treatment
•
AstraZeneca (AZ; NASDAQ: AZN) has secured an indication extension from the U.S. Food and Drug Administration (FDA) for its anti-eosinophil biologic Fasenra (benralizumab). The drug is now approved as an add-on maintenance treatment for severe asthma in pediatric patients aged 6 to 11 years with an eosinophilic phenotype, expanding its…
-
Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu
•
Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC) for a new indication of its antibody-based test, Ventana HER2 (4B5). This test serves as a companion diagnostic to identify breast cancer patients eligible for AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo’s (TYO: 4568) antibody-drug…
-
AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer
•
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its anti-PD-L1 drug Imfinzi (durvalumab) has successfully met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC). The trial’s success marks a significant milestone…
-
AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors
•
Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional indication by the US Food and Drug Administration (FDA) for their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan). The new indication authorizes the use of Enhertu as a treatment for unresectable or metastatic HER2-positive solid…
-
AstraZeneca and Daiichi Sankyo File for FDA Approval of Datopotamab Deruxtecan in Breast Cancer
•
AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, and its Japanese partner Daiichi Sankyo (TYO: 4568) have submitted a filing to the U.S. Food and Drug Administration (FDA) for their antibody-drug conjugate (ADC) datopotamab deruxtecan, aimed at treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adults who have previously…
-
Alexion’s Voydeya Earns FDA Nod as Add-on Therapy for PNH-Associated Extravascular Hemolysis
•
Alexion, the rare disease unit of AstraZeneca (AZ; NASDAQ: AZN) based in the UK, has secured regulatory approval from the US Food and Drug Administration (FDA) for its Factor D inhibitor Voydeya (danicopan). The drug is approved as an add-on therapy to ravulizumab or eculizumab, which are marketed as Ultomiris…
-
AstraZeneca’s AKT Inhibitor Truqap Approved in Japan for HR+, HER2- Breast Cancer
•
AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has registered with Japan’s Ministry of Health, Labour, and Welfare (MHLW) its first-in-class AKT inhibitor, Truqap (capivasertib), in combination with endocrine therapy Faslodex (fulvestrant). This combination therapy is intended for the treatment of unresectable or recurrent PIK3CA-, AKT1-, or PTEN-altered HR-positive, HER2-negative…
-
AstraZeneca’s Tralokinumab Trial Data Spurs Development of Brainomix’s e-Lung Software
•
AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic pulmonary fibrosis (IPF) candidate, tralokinumab, which has contributed to the development of Brainomix’s e-Lung software. This AI-enabled tool, announced by the UK medtech company this week, is designed to identify patients at risk of decline…
